New Generation Anticonvulsants for the Treatment of Epilepsy in Children

NeuroRx

Volumn 3, Issue 2, 2006, Pages 170-180

  Donner, Elizabeth J ^a   Snead III, O Carter ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

anticonvulsant; Antiepileptic drug (AED); children; epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; ATROPALDEHYDE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DRUG METABOLITE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PREGABALIN; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGITATION; ANHIDROSIS; ANOREXIA; ANTICONVULSANT ACTIVITY; ANXIETY; APLASTIC ANEMIA; ARTICLE; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BURNING SENSATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERTHERMIA; HYPONATREMIA; INCIDENCE; INFANTILE SPASM; INFECTION; INJECTION SITE PAIN; INTRACTABLE EPILEPSY; LENNOX GASTAUT SYNDROME; LIVER FAILURE; METABOLIC ACIDOSIS; MIGRAINE; MYOCLONUS; MYOCLONUS SEIZURE; MYOPIA; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; PAIN; PSYCHOSIS; QUALITY OF LIFE; RECEPTOR BLOCKING; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SWEATING; TACHYCARDIA; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; VISUAL FIELD DEFECT; WEIGHT GAIN; CHILD; PHARMACEUTICS; REVIEW;

ANTICONVULSANTS; CHILD; EPILEPSY; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646144219     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2006.01.013     Document Type: Article

References (77)

1. Chang B.S., and Lowenstein D.H. Epilepsy. N Engl J Med 349 (2003) 1257-1266
2. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
3. White H.S. Animal models of epileptogenesis. Neurology 12 Suppl 5 (2002) S7-S14
4. Shinnar S., and Berg A.T. Does antiepileptic drug therapy prevent the development of "chronic epilepsy"?. Epilepsia 37 (1996) 701-708
5. Dodson W.E. Pharmacokinetic principles of antiepileptic therapy in children. In: Pellock J.M., Dodson W.E., and Bourgeois B.F.D. (Eds). Pediatric epilepsy diagnosis and therapy. Ed 2 Vol 23 (2001), Demos Medical Publishing, New York 317-327
6. Dunn D.W. Neuropsychiatric aspects of epilepsy in children. EpilepsyBehav 4 (2003) 101-106
7. Shinnar S., and Pellock J.M. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 17 Suppl 1 (2002) S4-S17
8. Saint-Martin A.D., Seegmuller C., Carcangiu R., Kleitz C., Hirsch E., Marescaux C., and Metz-Lutz M.N. Cognitive consequences of rolandic epilepsy. Epileptic Disord 2 (2001) S159-S165
9. Camfield P., and Camfield C. Epileptic syndromes in childhood. clinical features, outcomes, and treatment. Epilepsia 43 Suppl 3 (2002) 27-32
10. Yung A.W., Park Y.D., Cohen M.J., and Garrison T.N. Cognitive and behavioral problems in children with centrotemporal spikes. Pediatr Neurol 23 (2000) 391-395
11. Helmstaedter C., Kurthen M., Lux S., Reuber M., and Elger C.E. Chronic epilepsy and cognition. a longitudinal study in temporal lobe epilepsy. Ann Neurol 54 (2003) 425-432
12. Miller V., Palermo T.M., and Grewe S.C. Quality of life in pediatric epilepsy. demographic and disease-related predictors and comparison with healthy controls. Epilepsy Behav 4 (2003) 36-42
13. Austin J.K., Huster G.A., Dunn D., and Risinger M.W. Adolescents with active or inactive epilepsy or asthma. a comparison of quality of life. Epilepsia 37 (1996) 1228-1238
14. Sillanpaa M., Jalava M., Kaleva O., et al. Long-term prognosis of seizures with onset in childhood. N Engl J Med 338 (1998) 1715-1722
15. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy. report of the ILAE task force on classification and terminology. Epilepsia 42 (2001) 796-803
16. Pellock J.M. Felbamate. Epilepsia 40 Suppl 5 (1999) S57-S62
17. LaRoche S.M., and Helmers S.L. The new antiepileptic drugs. scientific review. J Am Med Assoc 291 (2004) 605-614
18. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new antiepileptic drugs. a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61 (2004) 1-48
19. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 328 (1993) 29-33
20. Carmant L., Holmes G.L., Sawyer S., et al. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 125 (1994) 481-486
21. Leppik I.E. Felbamate. Epilepsia 36 Suppl 2 (1995) S66-S72
22. Glauser T.A., and Graves N.M. Phenytoin and fosphenytoin. In: Wyllie E. (Ed). The treatment of epilepsy. principles and practice. Ed 3 Vol 58 (2001), Lippincott Williams & Wilkins, Philadelphia 853-868
23. McLean M.J. Gabapentin. In: Wyllie E. (Ed). The treatment of epilepsy. principles and practice. Ed 3 Vol 62 (2001), Lippincott Williams & Wilkins, Philadelphia 853-868
24. Appleton R., Fichtner K., LaMoreaux L., et al. Gabapentin as add-on therapy in children with refractory partial seizures. a 12-week, multicenter, double-blind, placebo controlled study. Epilepsia 40 (1999) 1147-1154
25. Shapiro D.Y., Nordli D., Glauser T.A., Knapp L.E., Greiner M., Purcell T., Brigell M., Fichtner K., Kugler A.R., Malicsi M., Smith T.M., and Garofalo E.A. Gabapentin as add-on therapy for refractory partial seizures in children 1-36 months of age. a novel short-term, placebo-controlled trial. Epilepsia 41 Suppl 7 (2000) 106
26. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progess report on new antiepileptic drugs. a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51 (2002) 31-71
27. Bergin A.M., and Connolly M. New antiepileptic drug therapies. Neurol Clin N Am 20 (2002) 1163-1182
28. Gilliam F.G., and Gidal B.E. Lamotrigine. In: Wyllie E. (Ed). The treatment of epilepsy. principles and practice. Ed 3 Vol 63 (2001), Lippincott Williams & Wilkins, Philadelphia 853-868
29. Duchowny M., Pellock J.M., Graf W.D., et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 53 (1999) 1724-1731
30. Eriksson A.-S., Nergardh A., and Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy. a randomized, double-blind, crossover study. Epilepsia 39 (1998) 495-501
31. Motte J., Trevathan E., Arvidsson J.F.V., et al., The Lamictal Lennox-Gastaut Study Group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 337 (1997) 1807-1812
32. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash. risk/benefit considerations in adults and children. Epilepsia 40 (1999) 985-991
33. Yuen A.W.C., Land G., Weatherley B.C., et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33 (1992) 511-513
34. Wong I.C., and Lahtoo S.D. Adverse reactions to new anticonvulsant drugs. Drug Saf 23 (2000) 35-56
35. Beydoun A., Sachdeo R.C., Kutluay E., et al. Sustained efficacy and long term safety of oxcarbazepine. one-year open-label extension of a study in refractory partial seizures. Epilepsia 44 (2003) 1160-1165
36. Guerreiro M.M., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27 (1997) 205-213
37. Sillanpaa M.L. Carbamazepine and Oxcarbazepine. In: Wyllie E. (Ed). The treatment of epilepsy. principles and practice. Ed 3 Vol 56 (2001), Lippincott Williams & Wilkins, Philadelphia 853-868
38. Van Amelsvoort T., Bakshi R., Devaux C.B., et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy. a review. Epilepsia 35 (1994) 181-188
39. Smith P.E.M. Clinical recommendations for oxcarbazepine. Seizure 10 (2001) 87-91
40. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 Suppl 6 (2004) 13-18
41. Brodie M.J. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 Suppl 6 (2004) 19-27
42. Stratton S.C., Large C.H., Cox B., Davies G., and Hagan R.M. Effects of lamotrigine and levetiracetam on seizure-development in a rat amygdala kindling model. Epilepsy Res 53 (2003) 95-106
43. Lynch B., Lambeng N., Nocka K., Kensel-Hammes P., Bajjellieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 10 (2004) 9861-9866
44. Bourgeois B.F.D., Holder D.L., Valencia I., et al. Open label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia 42 Suppl 7 (2001) 253-254
45. Glauser T., Bebin M., Ritter F., et al. Open-label efficacy and safety of levetiracetam in pediatric patients with partial-onset seizures (abstract). Epilepsia 40 (1999) 161
46. Lagae L., Buyse G., and Deconinck A. Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Pediatr Neurol 7 (2003) 123-128
47. Kossoff E.H., Bergey G.K., Freeman J.M., et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 42 (2001) 1161-1163
48. Shinnar S., and Sommerville K.W. Tiagabine. In: Pellock J.M., Dodson W.E., and Bourgeois B.F.D. (Eds). Pediatric epilepsy diagnosis and therapy. Ed 2 Vol 37 (2001), Demos Medical Publishing, New York 489-498
49. Eckardt K.M., and Steinhoff B.J. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 39 (1998) 671-674
50. Ettinger A.B., Bernal O.G., Andriola M.R., Bagchi S., et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 40 (1999) 1159-1162
51. Snead O.C., Depaulis A., Vergnes M., and Marescaux C. Absence epilepsy. advances in experimental animal models. Adv Neurol 79 (1999) 253-278
52. Shinnar S., Berg A.T., Treiman D.M., Hauser W.A., Hesdorffer D.C., Scakellares J.C., Leppik I., Sillanpaa M., and Sommerville K.W. Status epilepticus and tiagabine therapy. review of safety data and epidemiologic comparisons. Epilepsia 42 (2001) 372-379
53. Krauss G.L., Johnson M.A., Sheth S., and Miller N.R. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74 (2003) 339-343
54. Kalviainen R., Hache J.C., and Renault-Dijouadi J.A. A study of visual fields in patients receiving tiagabine as monotherapy versus carbamazepine or lamotrigine monotherapy. Epilepsia 42 Suppl 7 (2001) 256
55. Schachter S.C. Tiagabine. In: Wyllie E. (Ed). The treatment of epilepsy. principles and practice. Ed 3 Vol 65 (2001), Lippincott Williams & Wilkins, Philadelphia 853-868
56. DeLorenzo R.J., Sombati S., Coulter D.A., et al. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41 Suppl 1 (2000) S40-S44
57. Gibbs III J.W., Sombati S., Delorenzo R.J., et al. Cellular actions of topiramate. blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 Suppl (2000) 510-516
58. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28 (1997) 167-179
59. Qian J., and Noebels J.L. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res 55 (2003) 225-233
60. Russo E., and Constanti A. Topiramate hyperpolarizes and modulates the slow poststimulus AAHP of rat olfactory cortical neurons in vitro. Br J Pharmacol 1441 (2004) 285-301
61. Gryder D.S., and Rogawski M.A. Selective antagonism of gluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23 (2003) 7069-7074
62. Angehagen M., Ben-Menachem E., Shank R., Ronback L., and Hanson E. Topiramate modulation of kainite-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 88 (2004) 320-356
63. Elterman R.D., Glauser T.A., Wyllie E., et al., Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 52 (1999) 1338-1344
64. Glauser T.A., Clark P.O., and Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 39 (1998) 1324-1328
65. Glauser T.A. Topiramate in the catastrophic epilepsies of childhood. J Child Neurol 15 Suppl 1 (2000) S14-S21
66. Sachdeo R.C., Glauser T.A., Ritter F., et al., Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52 (1999) 1882-1887
67. Grosso S., Galimberti D., Farnetani M.A., Cioni M., Mostardini R., Vivarelli R., Di Bartolo R.M., Bernardoni E., Berardi R., Morgese G., and Balestri P. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 14 (2005) 183-189
68. Battino D., Croci D., Rossini A., et al. Topiramate pharmacokinetics in children and adults with epilepsy. a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet 44 (2005) 407-416
69. Hammoudi D.S., Lee S.S.F., Madison A., et al. Reduced visual function associated with infantile spasms in children on vigabatrin therapy. Invest Ophthamol Visual Sci 46 (2005) 514-520
70. Mackay M.T., Weiss S.K., Adams-Webber T., et al. Practice parameter. medical treatment of infantile spasms. Neurology 62 (2004) 1668-1681
71. Curatolo P., Verdecchia M., and Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 23 (2001) 649-653
72. Westall C.A., Logan W.J., Smith K., Buncic J.R., Panton C.M., and Abdolell M. The Hospital for Sick Children, Toronto. Longitudinal ERG study of children on vigabatrin. Doc Ophthalmol 104 (2002) 133-149
73. Macdonald R.L., and Duche B. Zonisamide. mechanisms of action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs. Ed 5 (2002), Lippincott, Williams & Wilkins, Philadelphia 867-872
74. Brodie M.J., Duncan R., Vespignani H., et al. Dose-dependent safety and efficacy of zonisamide. a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 46 (2005) 31-41
75. Fisher R.S., Kerrigan III J.F., and Pellock J.M. Zonisamide. In: Pellock J.M., Dodson W.E., and Bourgeois B.F.D. (Eds). Pediatric epilepsy diagnosis and therapy. Ed 2 Vol 39 (2001), Demos Medical Publishing, New York 509-512
76. Beghi E. Efficacy and tolerability of the new antiepileptic drugs. comparison of two recent guidelines. Lancet Neurol 3 (2004) 618-621
77. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 (2004) 553-564